Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Di

Showing results (281-290 of 302) with videos related to

Pageof 31
Sort By:
Cancer|March 21, 2019
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trialKe-Da Yu, Si-Yu Wu, Guang-Yu Liu, et al.
The Lancet Regional Health. Western Pacific|July 30, 2021
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trialKe-Da Yu, Xi-Yu Liu, Li Chen, et al.
Breast Cancer Research and Treatment|March 18, 2008
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patientsNan-Yan Rao, Zhen Hu, Wen-Feng Li, et al.
Cancer Letters|April 13, 2026
Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancer PatientsXiao-Han Ying, Kun-Yu Zhang, Shu-Hao Jiang, et al.
Breast Cancer Research and Treatment|May 17, 2008
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
Breast Cancer Research and Treatment|May 1, 2008
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
BMJ (Clinical Research Ed.)|December 23, 2025
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialYin Liu, Yue Gong, Xiu-Zhi Zhu, et al.
Cell Discovery|December 19, 2023
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilitiesChao Chen, Cai-Jin Lin, Yu-Chen Pei, et al.
Science Advances|March 12, 2019
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradationXi Jin, Xiao-En Xu, Yi-Zhou Jiang, et al.
The Journal of Infection|May 14, 2024
Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: A randomized clinical trialHong-Han Ge, Ning Cui, Xiao-Hong Yin, et al.
Pageof 31

Showing results (281-290 of 302) with videos related to

Sort By:
Pageof 31
Cancer|March 21, 2019
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trialKe-Da Yu, Si-Yu Wu, Guang-Yu Liu, et al.
The Lancet Regional Health. Western Pacific|July 30, 2021
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trialKe-Da Yu, Xi-Yu Liu, Li Chen, et al.
Breast Cancer Research and Treatment|March 18, 2008
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patientsNan-Yan Rao, Zhen Hu, Wen-Feng Li, et al.
Cancer Letters|April 13, 2026
Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancer PatientsXiao-Han Ying, Kun-Yu Zhang, Shu-Hao Jiang, et al.
Breast Cancer Research and Treatment|May 17, 2008
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
Breast Cancer Research and Treatment|May 1, 2008
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
BMJ (Clinical Research Ed.)|December 23, 2025
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialYin Liu, Yue Gong, Xiu-Zhi Zhu, et al.
Cell Discovery|December 19, 2023
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilitiesChao Chen, Cai-Jin Lin, Yu-Chen Pei, et al.
Science Advances|March 12, 2019
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradationXi Jin, Xiao-En Xu, Yi-Zhou Jiang, et al.
The Journal of Infection|May 14, 2024
Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: A randomized clinical trialHong-Han Ge, Ning Cui, Xiao-Hong Yin, et al.
Pageof 31